文献速递前列腺癌

177Lu-PSMA放射性核素治疗在弥漫性骨髓受累患者中的疗效与安全性:多中心回顾性研究

Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study.
PubMed 文献 · Eur Urol · 2020-06-10

本研究回顾性分析了四中心43例基线PSMA PET显示弥漫性骨髓受累的mCRPC患者,接受154周期177Lu-PSMA治疗。12周时58%患者PSA下降≥50%,中位OS 11.6个月,3级贫血22%、血小板减少17%、中性粒细胞减少8%,4级血小板减少8%。结论认为疗效与安全性与II期证据相似,不应将超级骨扫描患者排除。

要点

  • 弥漫性骨髓受累患者接受177Lu-PSMA后58%达PSA50缓解。
  • 中位OS 11.6个月,中位疼痛进展时间8.3个月。
  • 3-4级血液学毒性常见但可接受,不应排除超级骨扫描患者。

核心结论

  • 弥漫性骨髓受累患者接受177Lu-PSMA的疗效与安全性与II期证据相似。
  • 可接受的安全性结果不支持将超级骨扫描患者排除在未来LuPSMA治疗方案之外。

研究设计与样本

  • 多中心回顾性研究,从全球四个中心的数据库中筛选出43例合格患者。
  • 患者接受177Lu-PSMA治疗共154个周期,来源于临床试验或同情用药项目。
  • 主要终点为PSA缓解(PCWG3)、血液学安全性(CTCAE)和总生存期。

主要发现

  • 中位基线PSA为1000(IQR 431-2151)ng/ml。
  • 12周时22例(58%)患者PSA下降至少50%。
  • 中位疼痛进展时间为8.3(95%CI 4.1-12.6)个月。
  • 中位总生存期为11.6(95%CI 8.8-14.3)个月。
  • 18例RECIST可测量病灶患者中7例(39%)报告淋巴结或内脏客观缓解。

关键数值与推荐

  • 3级贫血9例(22%),3级血小板减少7例(17%),3级中性粒细胞减少3例(8%)。
  • 4级血小板减少3例(8%)。

临床怎么用

  • 对于基线PSMA PET显示弥漫性骨髓受累的mCRPC患者,可考虑177Lu-PSMA治疗并密切监测血液学毒性。
  • 不应仅因超级骨扫描表现而将患者排除在LuPSMA治疗之外。

局限性

  • 回顾性研究设计,样本量较小(43例),来自四个中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 177Lu-labeled prostate-specific membrane antigen (LuPSMA) radionuclide therapy for metastatic castration-resistant prostate cancer is under investigation in a phase III trial (VISION: NCT03511664). However, patients with diffuse bone involvement, diagnosed with a "superscan" by bone scintigraphy at baseline, were excluded due to a lack of efficacy and safety data. We therefore aimed to investigate the feasibility of LuPSMA in patients with diffuse bone marrow involvement on baseline PSMA-targeted positron emission tomography. The primary end points were prostate-specific antigen (PSA) response (Prostate Cancer Working Group 3 [PCWG3]), hematologic safety profile (Common Terminology Criteria for Common Adverse Events [CTCAE]), and overall survival. Secondary end points of quality of life (assessed with Brief Pain Inventory-Short Form questionnaires) and radiologic response (Response Evaluation Criteria in Solid Tumors [RECIST]) were assessed. Through retrospective screening of databases, we identified 43 eligible patients across four centers worldwide who received 154 cycles of LuPSMA under clinical trials or compassionate access programs. Median baseline PSA was 1000 (interquartile range 431-2151) ng/ml. PSA decline of at least 50% at 12 wk was achieved in 22 (58%) patients, while median time to pain progression was 8.3 (95% confidence interval [CI] 4.1-12.6) mo. Median overall survival was 11.6 (95% CI 8.8-14.3) mo. Objective response in nodal or visceral disease was reported in seven (39%) of 18 patients with RECIST measurable disease. Grade 3 anemia, thrombocytopenia, and neutropenia occurred in nine (22%), seven (17%), and three (8%) patients, respectively. Grade 4 thrombocytopenia was noticed in three (8%) patients. In conclusion, patients with diffuse bone marrow involvement demonstrated similar LuPSMA efficacy and safety to phase II evidence. Acceptable safety outcomes do not support exclusion of patients with a superscan from future LuPSMA treatment protocols. PATIENT SUMMARY: In this report, we investigated the feasibility of prostate-specific membrane antigen (PSMA)-directed radionuclide treatment in patients with metastatic castration-resistant prostate cancer and diffuse bone involvement. We found that, despite a high load of bone metastases, PSMA-targeted therapy remains efficacious and safe when compared with the current phase II trial results.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gafita A, Fendler WP, Hui W, et al. Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. Eur Urol. 2020. PMID: 32532512. doi:10.1016/j.eururo.2020.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。